Fluoxetine but not Risperidone Increases Sociability in the BTBR Mouse Model of Autism

In the absence of a consistent specific biomarker, the diagnosis of autism is defined clearly defined central behavioral symptoms, ie abnormal social interaction and social communication, and repetitive behavior and / or restriction Based on interest. Many drugs, including fluoxetine and risperidone, have been used to treat symptoms associated with autism. Risperidone is an atypical antipsychotic that blocks the D2 and 5HT 2A receptors and has been approved by the US Food and Drug Administration (FDA) to reduce repetitive behavior and self-injurious behavior of autistic children.

Risperidone and aripiprazole are approved by the Food and Drug Administration (FDA) for the treatment of hypersensitivity associated with the diagnosis of Autism Spectrum Disorder. Risperidone is approved for children over the age of 5 years and aripiprazole is approved for use in children aged 6 and older. A double-blind, placebo-controlled trial conducted by the Children's Psychopharmacology Research Unit (RUPP) autistic network examined the risperidone therapeutic hypersensitivity associated with autism in 101 patients aged 5-17 years Sex 35 In this 8-week study, risperidone (average) dose 1.8 mg / d was compared. Severe Behavior Checklist The subcales of hypersensitivity and the overall improvement (clinical overall impression - improvement) scale 36-37 responses were significantly improved with decreasing hypersensitivity score ≧ 25% and on the CGI - 1 scale It was defined as a scored or very good score.

An eight-week double-blind, placebo-controlled study examined the effectiveness of risperidone on hypersensitivity of children with autism and other common developmental disorders. The risperidone group (mean dose 1.17 mg / day) was superior to the placebo group and reduced the hypersensitivity score of ABC 38. The weight gain in the risperidone group was significant, an average increase of 2.7 kg compared with 1 kg of the placebo group. The effectiveness of risperidone in children with autistic spectrum disorder was investigated in a 6-month randomized controlled trial 39. And I am irritated). The primary endpoint was the change in median childhood autism assessment scale from the baseline value and the average overall assessment scale for children from baseline values ​​and the risperidone group of 40 to 41 was superior to the placebo group It was.